BIOMAT Database Logo BIOMAT Database Logo

Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation. 2021

Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China.

Successes have been achieved in developing human monoamine oxidase B (hMAO-B) inhibitors as anti-Parkinson's disease (PD) drugs. However, low efficiency and unwanted side effects of the marketed hMAO-B inhibitors hamper their medical applications, therefore, novel potent selective hMAO-B inhibitors are still of great interest. Herein we report 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as hMAO-B inhibitors, which were designed by employing a fragment-based drug design strategy to link rasagiline to hydrophobic fragments. Among the synthesized 31 compounds, K8 and K24 demonstrated very encouraging hMAO-B inhibitory activities and selectivity over hMAO-A, better than rasagiline and safinamide. In vitro studies indicated that K8 and K24 are nontoxic to nervous tissue cells and they have considerable effects against ROS formation and potential neuroprotective activity. Further mice behavioral tests demonstrated these two compounds have good therapeutic effects on MPTP-induced PD model mice. All these experiment results suggest that compounds K8 and K24 can be promising candidates for further research for treatment of PD.

UI MeSH Term Description Entries
D007192 Indenes A family of fused-ring hydrocarbons isolated from coal tar that act as intermediates in various chemical reactions and are used in the production of coumarone-indene resins.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013438 Sulfhydryl Compounds Compounds containing the -SH radical. Mercaptan,Mercapto Compounds,Sulfhydryl Compound,Thiol,Thiols,Mercaptans,Compound, Sulfhydryl,Compounds, Mercapto,Compounds, Sulfhydryl
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
May 2019, Bioorganic & medicinal chemistry letters,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.
February 2018, European journal of medicinal chemistry,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
Design, synthesis and biological evaluation of novel indanones derivatives as potent acetylcholinesterase/monoamine oxidase B inhibitors.
October 2023, Future medicinal chemistry,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
2-Styrylchromone derivatives as potent and selective monoamine oxidase B inhibitors.
November 2019, Bioorganic chemistry,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors.
February 2010, Bioorganic & medicinal chemistry,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
5-Nitro-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one.
April 2012, Acta crystallographica. Section E, Structure reports online,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors.
January 2006, Current medicinal chemistry,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors.
May 2016, European journal of medicinal chemistry,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
Synthesis, SAR study, and biological evaluation of novel 2,3-dihydro-1H-imidazo[1,2-a]benzimidazole derivatives as phosphodiesterase 10A inhibitors.
August 2019, Bioorganic & medicinal chemistry,
Haiyan Kong, and Xianshe Meng, and Rui Hou, and Xiaoxiao Yang, and Jihong Han, and Zhouling Xie, and Yajun Duan, and Chenzhong Liao
Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.
March 2006, Chemical biology & drug design,
Copied contents to your clipboard!